StreetInsider.com News Articles

Form EFFECT Pulmatrix, Inc.

Fri, 23 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261023/27224600.html

Eos SENOLYTIX presents mouse survival data for aging drug PTC-2105

Thu, 22 Oct 2026 08:03:05 -0400

Eos SENOLYTIX, Inc. presented preclinical survival and healthspan data for its lead compound, PTC-2105, at the 17th World Congress on Targeting Mitochondria in Berlin, according to a company press release.

In naturally aged male mice treated from 80 weeks of age with a once-weekly 25 mg/kg dose of PTC-2105, overall survival was statistically significantly higher than in saline-treated controls (log-rank p = 0.0142). All saline-treated controls died by 137 weeks of age. A lower dose of 2.5 mg/kg did not show a significant overall survival benefit but showed improved cancer-specific survival in a competing-risks analysis (p = 0.0149).

One mouse from the

Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let

Thu, 22 Oct 2026 08:00:00 -0400

In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142)
“Speedy,” a PTC-2105-treated mouse now more than 167 weeks old, has outlived every saline-treated negative control in his study by more than 20% and remains active day and night
New “Team Speedy” webpage, launching today at eossenolytix.com/team-speedy, invites the public to watch Speedy, predict how far he will go, and sign up for milestone alerts

BERLIN and HOUSTON, Oct. 22,

Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let

Thu, 22 Oct 2026 08:00:00 -0400

In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142)
“Speedy,” a PTC-2105-treated mouse now more than 167 weeks old, has outlived every saline-treated negative control in his study by more than 20% and remains active day and night
New “Team Speedy” webpage, launching today at eossenolytix.com/team-speedy, invites the public to watch Speedy, predict how far he will go, and sign up for milestone alerts

BERLIN and HOUSTON, Oct. 22,

Form 425 Pulmatrix, Inc. Filed by: Pulmatrix, Inc.

Thu, 22 Oct 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20261022/27218409.html

Form 425 Pulmatrix, Inc. Filed by: Pulmatrix, Inc.

Tue, 13 Oct 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20261013/27176468.html

Form 424B3 Pulmatrix, Inc.

Wed, 07 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261007/27161288.html

Form DEFA14A Pulmatrix, Inc.

Wed, 07 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261007/27161263.html

Form ARS Pulmatrix, Inc. For: Dec 31

Mon, 05 Oct 2026 08:46:00 -0400

si-local-file:///var/storage/secattach/20261005/27146339.html

Form S-3/A Pulmatrix, Inc.

Mon, 05 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261005/27145113.html

Form EFFECT Pulmatrix, Inc.

Mon, 28 Sep 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260928/27109634.html

Form 424B3 Pulmatrix, Inc.

Fri, 25 Sep 2026 16:46:00 -0400

http://archive.fast-edgar.com/20260925/AB2ZI22CZZ2RG2QD229Q2WY2HMWSZZ22ZV82

Filed on: September 25, 2026

Form DEFM14A Pulmatrix, Inc.

Fri, 25 Sep 2026 16:43:00 -0400

http://archive.fast-edgar.com/20260925/A322W22CZZ2RI2QD229S2WY2QGH9HZ22Z282

Filed on: September 25, 2026

Form S-4/A Pulmatrix, Inc.

Wed, 23 Sep 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260923/27097116.html

Form 425 Pulmatrix, Inc. Filed by: Pulmatrix, Inc.

Tue, 22 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260922/27091067.html

Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria

Tue, 22 Sep 2026 08:30:00 -0400

Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine
Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesity
Eos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and metabolic health by targeting the underlying biological mechanisms of aging, today announced that it will

Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria

Tue, 22 Sep 2026 08:30:00 -0400

Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine
Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesity
Eos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions

Form S-4/A Pulmatrix, Inc.

Thu, 17 Sep 2026 16:38:00 -0400

http://archive.fast-edgar.com/20260917/AB2OI22CZZ2RG2Q3229Q2CY2HMWSZZ22Z282

Filed on: September 17, 2026

Pulmatrix (PULM) Reports Q2 Loss of $0.29

Thu, 13 Aug 2026 08:34:06 -0400

Pulmatrix (NASDAQ: PULM) reported Q2 EPS of ($0.29).

For earnings history and earnings-related data on Pulmatrix (PULM) click here.

Form 10-Q Pulmatrix, Inc. For: Jun 30

Thu, 13 Aug 2026 08:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26916997.html

Form 10-Q Pulmatrix, Inc. For: Jun 30

Thu, 13 Aug 2026 08:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26916997.html

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Thu, 13 Aug 2026 08:15:00 -0400

Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX

FRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its second quarter financial results for 2026 and provided a corporate update related to the merger agreement with Eos SENOLYTIX announced at the end of

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Thu, 13 Aug 2026 08:15:00 -0400

Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Thu, 13 Aug 2026 08:15:00 -0400

Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Thu, 13 Aug 2026 08:15:00 -0400

Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX